83-2270-37　［受注停止］GENLISA SARS-CoV-2 （Covid-19） Beta Neutralizing Antibody （B.1.351, B.1.351.2,B.1.351.3） ELISA 1 x 96 wells　KBVH420

特徴

• Description：ELISA for the Quantitative determination of neutralizing antibody to the SARS-CoV-2 receptor binding domain （RBD） of Beta variant （South Africa variant） in serum and plasma samples.
• One of the WHO's variants of concern, the beta coronavirus strain more than 8mutations in the spike protein, as well as several other mutations in other locations.
• Existing vaccines were moderately effective against the variant.
• As other Krishgen ELISA, these kits are based on monoclonal antibody detection for better sensitivity.
• A sandwich ELISA design and specific antibodies allow for a robust ELISA.
• Features include a standard, ready-to-use protocol, and the option to run serum or plasma samples.
• Detecting and quantifying neutralizing antibodies to SARS-CoV-2 offers important information in the evaluation of immune responses, development of vaccines and therapeutic drugs.
• The kit employs a blocking ELISA technique which mimics the virus neutralization process.
• Potent neutralizing antibodies often target the receptor interaction site in S1, disabling receptor interactions.
• The spike proteins of SARS-CoV-2 commonly bind to the human angiotensin converting enzyme 2 （ACE2） protein as a host receptor through their S1B domain.
• Receptor interaction is known to trigger irreversible conformational changes in coronavirus spike proteins enabling membrane fusion.
• SARS-CoV-2 initiates an immune response, which leads to the production of antibodies.
• These neutralizing antibodies disable host receptor interactions and prevent viral entry into the cell.
• They, therefore, also provide protection against future infection from SARS-CoV-2, as they remain in the circulatory system for months to years post infection.